Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma | Zendy

Georgina V. Long | Zendy; Daniil Stroyakovskiy | Zendy; Helen Gogas | Zendy; E. Levchenko | Zendy; Filippo de Braud | Zendy; James Larkin | Zendy; Claus Garbe | Zendy; Thomas Jouary | Zendy; Axel Hauschild | Zendy; JeanJacques Grob | Zendy; Vanna ChiarionSileni | Zendy; Célèste Lebbé | Zendy; Mario Mandalà | Zendy; Michael Millward | Zendy; Ana Arance | Zendy; Igor Bondarenko | Zendy; John B.A.G. Haanen | Zendy; Johan Hansson | Zendy; Jochen Utikal | Zendy; Virginia Ferraresi | Zendy; Н. В. Коваленко | Zendy; Peter Mohr | Zendy; Volodymyr Probachai | Zendy; Dirk Schadendorf | Zendy; Paul Nathan | Zendy; Caroline Robert | Zendy; Antoni Ribas | Zendy; Douglas J. DeMarini | Zendy; Jhangir G Irani | Zendy; Michelle Casey | Zendy; Danièle Ouellet | Zendy; AnneMarie Martin | Zendy; Ngocdiep T. Le | Zendy; Kiran Patel | Zendy; Keith T. Flaherty | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Author(s) -

Georgina V. Long,

Daniil Stroyakovskiy,

Helen Gogas,

E. Levchenko,

Filippo de Braud,

James Larkin,

Claus Garbe,

Thomas Jouary,

Axel Hauschild,

JeanJacques Grob,

Vanna ChiarionSileni,

Célèste Lebbé,

Mario Mandalà,

Michael Millward,

Ana Arance,

Igor Bondarenko,

John B.A.G. Haanen,

Johan Hansson,

Jochen Utikal,

Virginia Ferraresi,

Н. В. Коваленко,

Peter Mohr,

Volodymyr Probachai,

Dirk Schadendorf,

Paul Nathan,

Caroline Robert,

Antoni Ribas,

Douglas J. DeMarini,

Jhangir G Irani,

Michelle Casey,

Danièle Ouellet,

AnneMarie Martin,

Ngocdiep T. Le,

Kiran Patel,

Keith T. Flaherty

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1406037

Subject(s) - dabrafenib , trametinib , medicine , hazard ratio , melanoma , oncology , clinical endpoint , adverse effect , vemurafenib , interim analysis , confidence interval , randomized controlled trial , cancer research , mapk/erk pathway , biology , metastatic melanoma , kinase , microbiology and biotechnology

Combined BRAF and MEK inhibition, as compared with BRAF inhibition alone, delays the emergence of resistance and reduces toxic effects in patients who have melanoma with BRAF V600E or V600K mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research